Cell Signaling Technology establishes collaborative relationship with the Alliance for Cellular Signaling
Beverly, MA - January 9, 2002, Business Wire - Cell Signaling Technology (CST) announced today the establishment of a collaborative sponsorship of the Antibody Laboratory and the Protein Laboratory of the Alliance for Cellular Signaling (AFCS). Specifically, CST will be a preferred provider of “smart” or activation-state-specific antibodies relevant to the research of the AFCS. Additionally, CST will be a preferred provider for the development of antibodies to any novel target identified by the AFCS.
The overall goal of the Alliance for Cellular Signaling (www.signaling-gateway.org/) is to understand how cells interpret signals in a context-dependent manner. The process will involve identification of all the proteins that comprise the various signaling systems, the assessment of time-dependent information flow through the systems in both normal and pathological states, and finally the reduction of the mass of detailed data into a set of interacting theoretical models that describe cellular signaling.
“CST’s activation-state-specific antibodies are proving to be enormously useful in our efforts to monitor modulation in the phosphorylation state of proteins of interests,” said Dr. Susanne Mumby, Director of the Antibody Laboratory. “We look forward to collaborating with CST on the development of additional antibodies to novel proteins and sites of modification that will be revealed by the proteomics effort of the Alliance.”
“The Alliance for Cellular Signaling represents a paradigm shift,” said Chris Bunker, Director of Pharma Services of CST. “Having leading cell biologists make their research objectives and experimental results immediately and freely available via the web will help rapidly expand our understanding of cell biology and signal transduction.”